cancer general content image The Cancer Section of Imperial Clinical Trials Unit (ICTU-Ca) is based at Imperial College’s Hammersmith Campus.  Led by Professor Michael Seckl, Imperial AHSC Cancer Clinical Trials Lead, the cancer team supports trials in all phases of drug development across multiple sites of disease (breast, gastrointestinal, gynaecological and brain).  The cancer portfolio exploits the research expertise in the Division of Cancer to enable trials that include new and exciting imaging modalities, translational research initiatives and innovative study designs as they evolve.

The ICTU-Cancer Team supports trials led by Professor Michael Seckl, Professor Andrea Rockall, Dr Jonathan Krell and Dr Maria Kyrgiou. Examples of ICTU adopted trials include:

  • DICE: An international multi-centre, randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma).
  • Radical: A single arm phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients who have progressed on treatment with anastrozole or letrozole. Please find RADICAL Study Protocol (pdf)
  • MALIBO: Development and application of MAchine Learning In whole Body MRI with diffusion weighted imaging in the staging Oncology patients.
  • NOVEL: Nonavalent prophylactic HPV vaccine (GARDASIL9) after local conservative treatment for cervical intra-epithelial neoplasia: a randomised controlled trial.
  • CURESPONSE |  Prediction of Patient Drug Response Using an Ex Vivo Organ Culture (EVOC) on fresh tumour samples from Metastatic Patients

  • REFINE-Lung:  A randomised open-label phase III trial of reduced frequency pembrolizumab immunotherapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.


For further information on ICTU-Cancer, please click here.